Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA ; volume:11 ; number:5 ; day:9 ; month:8 ; year:2024 ; pages:1291-1302 ; date:10.2024
Rheumatology and therapy ; 11, Heft 5 (9.8.2024), 1291-1302, 10.2024
- Creator
-
Strand, Vibeke
Bender, Shaun
McCabe, Dorothy
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-024-00687-w
- URN
-
urn:nbn:de:101:1-2412102102147.258178066779
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Strand, Vibeke
- Bender, Shaun
- McCabe, Dorothy
- SpringerLink (Online service)
Other Objects (12)
Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
AVT02: An Adalimumab Biosimilar
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Efficacy of adalimumab in sarcoidosis
Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
AVT02: An Adalimumab Biosimilar
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Efficacy of adalimumab in sarcoidosis
Summary of Research: Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
AVT02: An Adalimumab Biosimilar
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis